Matthew R. Reese
Pfizer (United States)(US)PRX Research
Publications by Year
Research Areas
Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Catalytic C–H Functionalization Methods
Most-Cited Works
- → An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19(2021)1,855 cited
- → Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19(2021)288 cited
- → Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19(2020)159 cited
- → Sulfonamide Synthesis via Calcium Triflimide Activation of Sulfonyl Fluorides(2018)118 cited
- → Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia(2012)89 cited
- → Ru/Ni Dual Catalytic Desulfinative Photoredox Csp2–Csp3 Cross-Coupling of Alkyl Sulfinate Salts and Aryl Halides(2017)73 cited
- → High‐Throughput Ligand Screening Enables the Enantioselective Conjugate Borylation of Cyclobutenones to Access Synthetically Versatile Tertiary Cyclobutylboronates(2019)72 cited
- → A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19(2024)61 cited
- → Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1(2004)57 cited
- → Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1 H -pyrazolo-[3,4- b ]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator(2014)51 cited